{"id":"https://openalex.org/W4320719369","doi":"https://doi.org/10.1089/nat.2022.0073","title":"Considerations for the Terminal Sterilization of Oligonucleotide Drug Products","display_name":"Considerations for the Terminal Sterilization of Oligonucleotide Drug Products","publication_year":2023,"publication_date":"2023-02-14","ids":{"openalex":"https://openalex.org/W4320719369","doi":"https://doi.org/10.1089/nat.2022.0073","pmid":"https://pubmed.ncbi.nlm.nih.gov/36787481","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10277985"},"language":"en","primary_location":{"id":"doi:10.1089/nat.2022.0073","doi":"https://doi.org/10.1089/nat.2022.0073","is_oa":true,"landing_page_url":"https://doi.org/10.1089/nat.2022.0073","pdf_url":"https://www.liebertpub.com/doi/pdf/10.1089/nat.2022.0073?download=true","source":{"id":"https://openalex.org/S2489440031","display_name":"Nucleic Acid Therapeutics","issn_l":"2159-3337","issn":["2159-3337","2159-3345"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nucleic Acid Therapeutics","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.liebertpub.com/doi/pdf/10.1089/nat.2022.0073?download=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032074930","display_name":"Daniel P. DeCollibus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Paul Decollibus","raw_affiliation_strings":["Drug Product Technology and Engineering, Amgen, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Product Technology and Engineering, Amgen, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110085702","display_name":"Justin Searcy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Justin Searcy","raw_affiliation_strings":["Pharmaceutical Development, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065328002","display_name":"Anna Tivesten","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anna Tivesten","raw_affiliation_strings":["CVRM CMC Projects, Pharmaceutical Sciences, AstraZeneca R&D, Gothenburg, Sweden","CVRM CMC Projects, Pharmaceutical Sciences, AstraZeneca R&D, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CVRM CMC Projects, Pharmaceutical Sciences, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"CVRM CMC Projects, Pharmaceutical Sciences, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001400339","display_name":"Nadim Akhtar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nadim Akhtar","raw_affiliation_strings":["New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom","New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111523641","display_name":"Christian Lindenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Christian Lindenberg","raw_affiliation_strings":["Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland","Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001899971","display_name":"Nounja Abarrou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Nounja Abarrou","raw_affiliation_strings":["Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland","Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080539612","display_name":"Sujana Pradhan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sujana Pradhan","raw_affiliation_strings":["GSK, Strategic External Development, Analytical Development, Collegeville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Strategic External Development, Analytical Development, Collegeville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001626083","display_name":"Maggie Fiandaca","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maggie Fiandaca","raw_affiliation_strings":["GSK, Strategic External Development, Analytical Development, Collegeville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Strategic External Development, Analytical Development, Collegeville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000347089","display_name":"Jenny Franklin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenny Franklin","raw_affiliation_strings":["CMC Regulatory Affairs, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CMC Regulatory Affairs, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005372852","display_name":"Geetha N. Govindan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geetha Govindan","raw_affiliation_strings":["Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA","Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077014232","display_name":"Hung\u2010Yi Liu","orcid":"https://orcid.org/0000-0002-2414-2885","observed_orcids":["https://orcid.org/0000-0002-2414-2885"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hung-Yi Liu","raw_affiliation_strings":["Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA","Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"Pharmaceutical Operations & Technology, Biogen, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Royle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Royle","raw_affiliation_strings":["New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom","New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036155949","display_name":"Patrick Lim Soo","orcid":"https://orcid.org/0009-0001-3477-9222","observed_orcids":["https://orcid.org/0009-0001-3477-9222"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Lim Soo","raw_affiliation_strings":["Pharmaceutical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Andover, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Andover, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005802512","display_name":"Kirsten Storch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kirsten Storch","raw_affiliation_strings":["Pharma Technical Development, Roche Diagnostics GmbH, Mannheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Technical Development, Roche Diagnostics GmbH, Mannheim, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5110085702"],"corresponding_institution_ids":["https://openalex.org/I2800035258"],"apc_list":null,"apc_paid":null,"fwci":0.5032,"has_fulltext":true,"cited_by_count":18,"citation_normalized_percentile":{"value":0.37091988,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"33","issue":"3","first_page":"159","last_page":"177"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11455","display_name":"Microbial Inactivation Methods","score":0.263700008392334,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11455","display_name":"Microbial Inactivation Methods","score":0.263700008392334,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.2581000030040741,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.18619999289512634,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/terminal-sterilization","display_name":"terminal sterilization","score":0.9229999780654907},{"id":"https://openalex.org/keywords/oligonucleotide-therapeutics","display_name":"oligonucleotide therapeutics","score":0.8930000066757202},{"id":"https://openalex.org/keywords/parenteral-drug-products","display_name":"parenteral products","score":0.9409999847412109},{"id":"https://openalex.org/keywords/sterility-assurance","display_name":"sterility assurance","score":0.777999997138977},{"id":"https://openalex.org/keywords/membrane-sterilization","display_name":"membrane sterilization","score":0.8849999904632568},{"id":"https://openalex.org/keywords/aseptic-processing","display_name":"aseptic processing","score":0.9079999923706055},{"id":"https://openalex.org/keywords/heat-treatment-food-and-biological-processing","display_name":"heat treatment (food and biological processing)","score":0.6970000267028809},{"id":"https://openalex.org/keywords/ionizing-radiation","display_name":"ionizing radiation","score":0.9290000200271606},{"id":"https://openalex.org/keywords/chemistry-manufacturing-and-controls","display_name":"chemistry, manufacturing and controls","score":0.8159999847412109},{"id":"https://openalex.org/keywords/regulatory-expectations","display_name":"regulatory expectations","score":0.8450000286102295}],"concepts":[{"id":"https://openalex.org/C148761745","wikidata":"https://www.wikidata.org/wiki/Q1563203","display_name":"Sterilization (economics)","level":4,"score":0.609544575214386},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4952224791049957},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.3647669553756714},{"id":"https://openalex.org/C183696295","wikidata":"https://www.wikidata.org/wiki/Q2487696","display_name":"Biochemical engineering","level":1,"score":0.35227513313293457},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.27422818541526794},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.25916099548339844},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.24365106225013733},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.12017443776130676},{"id":"https://openalex.org/C536366893","wikidata":"https://www.wikidata.org/wiki/Q66076","display_name":"Foreign exchange market","level":3,"score":0.0},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0},{"id":"https://openalex.org/C2776988154","wikidata":"https://www.wikidata.org/wiki/Q66100","display_name":"Exchange rate","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013242","descriptor_name":"Sterilization","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1089/nat.2022.0073","doi":"https://doi.org/10.1089/nat.2022.0073","is_oa":true,"landing_page_url":"https://doi.org/10.1089/nat.2022.0073","pdf_url":"https://www.liebertpub.com/doi/pdf/10.1089/nat.2022.0073?download=true","source":{"id":"https://openalex.org/S2489440031","display_name":"Nucleic Acid Therapeutics","issn_l":"2159-3337","issn":["2159-3337","2159-3345"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nucleic Acid Therapeutics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10277985","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10277985","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10277985/pdf/nat.2022.0073.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nucleic Acid Ther","raw_type":"Text"},{"id":"pmid:36787481","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36787481","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nucleic acid therapeutics","raw_type":"Review"},{"id":"pmh:oai:oak.novartis.com:48784","doi":null,"is_oa":false,"landing_page_url":"https://oak.novartis.com/48784/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400709","display_name":"The Novartis Repository (Novartis)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1283582996","host_organization_name":"Novartis (Switzerland)","host_organization_lineage":["https://openalex.org/I1283582996"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1089/nat.2022.0073","doi":"https://doi.org/10.1089/nat.2022.0073","is_oa":true,"landing_page_url":"https://doi.org/10.1089/nat.2022.0073","pdf_url":"https://www.liebertpub.com/doi/pdf/10.1089/nat.2022.0073?download=true","source":{"id":"https://openalex.org/S2489440031","display_name":"Nucleic Acid Therapeutics","issn_l":"2159-3337","issn":["2159-3337","2159-3345"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nucleic Acid Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.6240000128746033,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4320719369.pdf","grobid_xml":"https://content.openalex.org/works/W4320719369.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1773941282","https://openalex.org/W1966067528","https://openalex.org/W1977721810","https://openalex.org/W1978868487","https://openalex.org/W1990548509","https://openalex.org/W2006576308","https://openalex.org/W2025805318","https://openalex.org/W2026597923","https://openalex.org/W2062423674","https://openalex.org/W2072767862","https://openalex.org/W2091486354","https://openalex.org/W2095663425","https://openalex.org/W2097637676","https://openalex.org/W2112585917","https://openalex.org/W2143177607","https://openalex.org/W2173634938","https://openalex.org/W2767250352","https://openalex.org/W2794834053","https://openalex.org/W2797978148","https://openalex.org/W2804284909","https://openalex.org/W2864331328","https://openalex.org/W2889293524","https://openalex.org/W2944263240","https://openalex.org/W3023447766"],"related_works":["https://openalex.org/W4416528227","https://openalex.org/W2417524540","https://openalex.org/W4245750749","https://openalex.org/W7204015278","https://openalex.org/W2124447756","https://openalex.org/W2804284909","https://openalex.org/W2185707236","https://openalex.org/W4409914313","https://openalex.org/W4403547696","https://openalex.org/W2024759369"],"abstract_inverted_index":{"A":[0],"primary":[1],"function":[2],"of":[3,14,104,114,129,147,165,194],"the":[4,15,33,39,50,162,172,189],"parenteral":[5,25],"drug":[6,26,34,82,135,168,212],"product":[7,35,51,169,181],"manufacturing":[8],"process":[9],"is":[10,36,53],"to":[11,86,96,121,139,175,186,210],"ensure":[12],"sterility":[13,72],"final":[16,40],"product.":[17],"The":[18],"two":[19],"most":[20],"common":[21],"methods":[22],"for":[23,109,180],"sterilizing":[24],"products":[27,83],"are":[28,84,137],"terminal":[29],"sterilization":[30,76],"(TS),":[31],"whereby":[32,49],"sterilized":[37,54],"in":[38,63,134,188],"container":[41],"following":[42],"filling":[43],"and":[44,46,58,77,126,151,183,192,203],"finish,":[45],"membrane":[47,56,75],"sterilization,":[48,182],"stream":[52],"by":[55],"filtration":[57],"filled":[59],"into":[60],"presterilized":[61],"containers":[62],"an":[64,101],"aseptic":[65,78],"processing":[66],"environment.":[67],"Although":[68],"TS":[69,87,195],"provides":[70],"greater":[71],"assurance":[73],"than":[74],"processing,":[79,170],"not":[80],"all":[81],"amenable":[85],"processes,":[88],"which":[89],"typically":[90],"involve":[91],"heat":[92],"treatment":[93],"or":[94],"exposure":[95],"ionizing":[97],"radiation.":[98],"Oligonucleotides":[99],"represent":[100],"emerging":[102],"class":[103],"therapeutics":[105],"with":[106],"great":[107],"potential":[108],"treating":[110],"a":[111,144],"broad":[112],"range":[113],"indications,":[115],"including":[116],"previously":[117],"undruggable":[118],"targets.":[119],"Owing":[120],"their":[122,155],"size,":[123],"structural":[124],"complexity,":[125],"relative":[127],"lack":[128],"governing":[130],"regulations,":[131],"several":[132],"challenges":[133],"development":[136,193],"unique":[138],"oligonucleotides.":[140],"This":[141],"exceptionality":[142],"justifies":[143],"focused":[145],"assessment":[146],"traditional":[148],"chemistry,":[149],"manufacturing,":[150],"control":[152],"strategies":[153],"before":[154],"adoption.":[156],"In":[157],"this":[158],"article,":[159],"we":[160],"review":[161],"current":[163,200],"state":[164],"sterile":[166],"oligonucleotide":[167,211],"highlight":[171],"key":[173],"aspects":[174],"consider":[176],"when":[177],"assessing":[178],"options":[179],"provide":[184,204],"recommendations":[185],"aid":[187],"successful":[190],"evaluation":[191],"processes.":[196],"We":[197],"also":[198],"explore":[199],"regulatory":[201],"expectations":[202],"our":[205],"interpretation":[206],"as":[207],"it":[208],"pertains":[209],"products.":[213]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2023-02-15T00:00:00"}